Can a targeted pill plus chemo shrink lung tumors before surgery?
NCT ID NCT05430802
First seen Jul 22, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether giving the targeted drug furmonertinib along with standard chemotherapy before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II to IIIB). Participants take furmonertinib daily for 9 weeks plus three cycles of cisplatin and pemetrexed, then undergo surgery. The study aims to see how many patients respond to this pre-surgery treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- furmonertinib combined with cisplatin and pemetrexed
- What this could lead to
- If successful, this approach could shrink tumors before surgery, potentially improving outcomes for people with EGFR-mutated lung cancer.
- What could go wrong
- This is an early-phase, single-arm trial with only 40 participants. It may not prove better than standard treatment, and the drug combination carries risks like chemotherapy side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2022
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * With written informed consent before any study procedure * Histology or cytology diagnose of non-small cell lung cancer within 60 days * Stage IIA-IIIB (T3N2M0 only), with resectable lesion(s) by radiology * EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations) * Without prior anti-tumor treatment * With at least one measurable lesions * ECOG performance status 0-1 * Using adequate and effective contraception, women should refrain from breastfeeding and have a negative pregnancy test prior to the first administration of the study drug if within during child-bearing age Exclusion Criteria: * EGFR Exon 20 insertions positive * Mixed with small cell cancer, or other mixed types of lung cancer * Any prior anti-tumor treatment * Major surgery within 4 weeks before enrollment * Women with pregnancy or breastfeeding * Use of strong CYP3A4 inhibitors within 7 days or strong CYP3A4 inducers within 21 days before enrollment; use of traditional Chinese medicine with anti-tumor effect within 21 days before enrollment * With history of other malignancy except for radical resected tumors without recurrence for 5 years or more * With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active HBV/HCV/HIV or other infections requiring infusion treatment * Severe gastrointestinal diseases which may affect the intake and absorption of study drug * Prolongation of ECG QTc or with relative risk factors * History of interstitial lung disease or with relative risk factors * Inadequate organ function of hematology, liver and kidney * Allergic to study drugs or any component * Poor adherence or other situation judged by investigator * Patients who had participated other clinical studies of tumors
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non small cell lung cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tangdu Hospital
Xi'an, Shannxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink advanced solid tumors?
- Can a targeted drug delivery system shrink lung tumors?
- Can a new drug shrink tumors that resist standard care?
- Can a Three-Dose immunotherapy cure early lung cancer without surgery?
- Can a new drug shrink advanced solid tumors?
- Can a less extensive lung cancer surgery be just as effective?